Our Board of Directors
Michael Sneddon
Chairman
Michael Sneddon is a seasoned entrepreneur with a wealth of global expertise that spans over three decades. He is widely recognized for his achievements in business and his exceptional leadership skills. Mr. Sneddon obtained a bachelor’s degree in civil engineering with a cluster in programming and software development from the University of Nebraska. He further honed his skills by studying Law and Business Management at Brigham Young University, where he earned a J.D./MBA degree.
After his studies, Mr. Sneddon co-founded MultiLing Corporation, an international language services provider specializing in IP translations. As CEO at MultiLing and over two decades of continuous improvement, he built the company to 250 employees and eight offices, seven of which were overseas. Under his leadership, the company developed and implemented world-class technology in terminology management, translation automation, and global workflow technology. This, plus consistent double-digit organic growth, enabled MultiLing to become the world's most profitable translation company with the highest EBITDA, measured as a percentage of revenue.
Mr. Sneddon's extensive international experience allowed him to become fluent in German, as well as conversationally fluent in Spanish and Swedish. He gained a deep understanding of Asian and European business cultures and norms. Michael Sneddon is a rare entrepreneur and business leader. He is one of the few founders to conceive a business concept, start a global enterprise from scratch, grow it organically, and years later execute a sale at high P/E ratio.
Outside of his business endeavors, Mr. Sneddon is an avid skier, scuba diver, cyclist, mountain runner, and traveler. He is also an ardent reader and has completed several triathlons, including the Florida Ironman. He is passionate about fitness and personal growth. Mr. Sneddon is a well-rounded individual who has achieved excellence in both his professional and personal pursuits.
Dr. Paul Shami
Board of Directors
Dr. Shami is a Professor in the Division of Hematology and Hematologic Malignancies and member of the Huntsman Cancer Institute at the University of Utah. Dr. Shami has 25 years of experience in the treatment of cancer with a particular emphasis on hematologic malignancies. He also has more than 25 years of experience in cancer drug development, ranging from drug discovery to all phases of clinical trials. Dr. Shami served on the Developmental Therapeutics Study Section at the NCI and serves on the AML and myelodysplastic syndromes panels of the National Cancer Center Network.
Dr. Shami was the first investigator to observe that O2-aryl diazeniumdiolate NO donors are potent treatments for cancer. He is also the inventor of the micellar formulation of JS-K. In addition to JSK Therapeutics™, Dr. Shami is the co-founder of Lone Star Thiotherapies, a start-up company aiming at developing thiocarbamate/metal chelates for the treatment of cancer.
Randall T. Peterson, PhD
Board of Directors
Randall T. Peterson, PhD is a chemical biologist whose research utilizes high-throughput screening technologies to discover new drug candidates for cardiovascular and nervous system disorders. Unlike conventional drug discovery programs that utilize simplified, in vitro assays, the Peterson lab screens using living zebrafish, ensuring that the drug candidates discovered are active in vivo. Several of the compounds discovered by the Peterson laboratory have become widely used research tools or preclinical drug candidates.
Dr. Peterson received his PhD from Harvard University where he studied as a Howard Hughes Medical Institute predoctoral fellow in the laboratory of Stuart Schreiber. He completed a postdoctoral fellowship with Mark Fishman at Massachusetts General Hospital. Dr. Peterson spent 14 years as a faculty member at Harvard University where he was the Charles Addison and Elizabeth Ann Sanders Chair in Basic Science at Harvard Medical School, Scientific Director of the MGH Cardiovascular Research Center, and Senior Associate Member of the Broad Institute. In 2017 he moved to the University of Utah as L.S. Skaggs Presidential Endowed Professor and Dean of the College of Pharmacy.
Joseph Nowoslawski, MD
CEO Board Designee
Dr. Nowoslawski earned a Bachelor’s Degree in Biology from Wayne State University and a Medical Degree from Michigan State University. He trained at one of the first residencies in Emergency Medicine at the Medical College of Pennsylvania. Dr. Nowoslawski has over 30 years experience as a medical doctor and healthcare executive. He founded American Hospital Services Group (AHSG), a health care delivery and staffing company. He served as AHSG’s Medical Director reviewing aspects of healthcare delivery systems under healthcare reform initiatives as well as directing the company to successfully obtain an award from the United States Air Force exceeding $1 billion dollars. Dr. Nowoslawski has orchestrated the first strategic sourcing contract for his company in the state of Pennsylvania for all of the healthcare services provided in the state.
Dr. Nowoslawski is also a seasoned venture capital investor with extensive involvement in the venture community in Utah having invested in biotech startup companies in the region. He is a member of the Salt Lake City Angels investment group, the Purpose Investor Network and is an active member of Bio Utah. He has taught funding approaches for startups in the region and works with several philanthropic fund raising projects. Prior to founding AHSG, Dr. Nowoslawski practiced clinically for a number of years in the SE Pennsylvania region, including maintaining the Directorships of Emergency Departments in the region.